Drug

Nepafenac

Approved · EMA

Late-stage development

Also known as 2-amino-3-benzoylbenzeneacetamide, Ilevro, Nevanac, Nepafenaco+1 more

2-amino-3-benzoylbenzeneacetamide, Ilevro, Nevanac, Nepafenaco, Nepafenacum.

RxNorm298665 ChEMBLCHEMBL1021UNII0J9L7J6V8C

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1% TID for Treatment of Ocular Inflammation Associated With Cataract Surgery

Clinical trial2020-10-28Results posted · ClinicalTrials.gov

Macular Edema Nepafenac vs. Difluprednate Uveitis Trial

Clinical trial2020-03-31Terminated · ClinicalTrials.gov

Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial

Clinical trial2019-03-01Completed · ClinicalTrials.gov

Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD for Treatment of Ocular Inflammation Associated With Cataract Surgery

Clinical trial2018-11-14Results posted · ClinicalTrials.gov

Phase 2 Randomized, Double-blind Clinical Trial to Evaluate Efficacy and Safety of the Ophthalmic Solution PRO-155 Versus Nevanac 0.1% Ophthalmic Solution in Post Phacoemulsification Patients

Clinical trial2018-10-30Results posted · ClinicalTrials.gov

Vitreous pge2 Level Changes After Topical Administration of Diclofenac 0.1%, Nepafenac 0.3%, Indomethacin 0.5% and Bromfenac 0.09% in Vitrectomy Patients

Clinical trial2018-07-09Completed · ClinicalTrials.gov

Comparison of Dropless Prophylaxis After Routine Phacoemulsification to Standard Drops Regimen

Clinical trial2018-02-23Results posted · ClinicalTrials.gov

Comparison of Diclofenac vs. Nepafenac Ophthalmic Drops: Patient Comfort

Clinical trial2016-01-01Primary completion · ClinicalTrials.gov

Efficacy of Topic Antiinflammatory Therapy Treatment in Center Point Thickness Secondary to Selective Photocoagulation in Diabetic Macular Edema

Clinical trial2015-03-01Completed · ClinicalTrials.gov

Comparison of Ketorolac Tromethamine 0.4% and Nepafenac 0.1% for the Prevention of Cystoid Macular Edema After Phacoemulsification: Prospective Randomized Double-masked Study

Clinical trial2014-02-01Completed · ClinicalTrials.gov

Effect of Nepafenac Eye Drops on Intraocular Pressure - a Randomized Prospective Study

Clinical trial2013-04-01Completed · ClinicalTrials.gov

Approval: Nevanac (EMA)

Regulatory2007-12-11EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Nepafenac

Aliases & brands

2-amino-3-benzoylbenzeneacetamideIlevroNevanacNepafenacoNepafenacum

RxNorm CUI

298665

ChEMBL ID

CHEMBL1021

UNII

0J9L7J6V8C

Regulatory jurisdictions

ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

2007-12-11

Latest approval

2007-12-11

Authorities

EMA

Total events

emaEuropean Medicines Agency· 1 event

2007-12-11Approval

Approval: Nevanac (EMA)

Indication: Nevanac is indicated for: prevention and treatment of postoperative pain and inflammation associated with cataract surgery; reduction in the risk of postoperative macular oedema… Show full indication

Nevanac is indicated for: prevention and treatment of postoperative pain and inflammation associated with cataract surgery; reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.